---
name: Adeno-associated virus (AAV) * VVector Bio
slug: vvectorbio
site: cro
website_domain: vvectorbio.com
summary: Adeno-associated virus (AAV) * VVector Bio provides CRO services. Discovery_source:brave.
tagline: Cost-effective AAV and viral vector manufacturing technologies for cell and gene therapies.
founded_year: 
employee_count_band: 
employee_count_label: 
parent_name: 
parent_slug: 
hq_country: 
tier2_domain_verified: false
updated_at: 2026-06-10T01:44:44.955Z
services_count: 1
modalities_count: 3
indications_count: 2
locations_count: 0
review_signal_gate: closed
generated_by: BioBM Editorial AI
---

# Adeno-associated virus (AAV) * VVector Bio

Cost-effective AAV and viral vector manufacturing technologies for cell and gene therapies.

Listed on cro.directory.

## Summary

Adeno-associated virus (AAV) * VVector Bio provides CRO services. Discovery_source:brave.

## Services

- Translational Research

## Modalities

- Cell Therapy
- Gene Therapy
- AAV / Viral Vector Platform

## Indications

- Infectious Disease
- Oncology

## Long description

VVector Bio is a spin-out of McGill University developing cutting-edge technologies for cost-effective manufacturing of cell and gene therapies. The company specializes in advanced plasmid and cell systems leveraging functional genomics to improve AAV yields and quality by orders of magnitude compared to industry standards.

**Core Capabilities:**

- **AAV Single Plasmid Technology (SAAVANA™):** Single-plasmid transfection platform available for licensing that reduces plasmid production costs by up to 66%.
- **Viral Vector Plasmids:** Provides plasmids containing Rep2-Cap serotypes 2, 5, 6, 8, and 9 for AAV production; packaging plasmids and transfer vectors for 2nd and 3rd generation lentivirus vectors; FastBac system for rapid bacmid generation for baculovirus-based AAV assembly in insect cells; pAdEasy adenoviral vector system for adenovirus production in HEK-293 cells.
- **Process Development & Tech Transfer:** Extensive hands-on experience in process development with seamless tech transfer to GMP facilities up to 50-L scale.
- **Gene Synthesis & Cloning:** Can proceed with projects using only gene sequences, performing chemical synthesis and cloning into plasmid vectors with amplification to required scale.
- **Viral Vector Production:** Manufactures non-infectious, non-replicative AAV, lentivirus, and adenovirus vectors. AAV produced in HEK-293 cells (BSL-2); lentivirus for ex-vivo CAR-T cell therapy; adenovirus for vaccination, gene therapy, and cancer therapy applications.

**Typical Project Timelines:** AAV (HEK-293) ~6 weeks; Lentivirus ~6 weeks; Adenovirus ~8 weeks; AAV (insect cell system) ~8 weeks.

_Profile last updated: 2026-06-10T01:44:44.955Z. Profile facts may include AI-assisted enrichment._

Auto-generated by BioBM Editorial AI for machine-readable profile access.